Cannabidiol inhibits both human Kv7.1 and Kv7.1/KCNE1 channels through distinct sites
Unlocking CBD's Dual Mechanism in Cardiac Ion Channels for Safer Drug Development
Our AI-powered analysis reveals critical insights into Cannabidiol's distinct inhibitory action on cardiac and epithelial Kv7.1 and Kv7.1/KCNE1 channels, identifying unique binding sites. This foundational research guides the development of subtype-selective Kv7 modulators, mitigating adverse cardiac effects.
Executive Impact Summary
This study leverages a comprehensive methodology including AI-driven structural predictions (Chai-1 model), site-directed mutagenesis, electrophysiological validation, and molecular dynamics simulations to elucidate cannabidiol's (CBD) inhibitory mechanisms. We've identified two unique binding sites: an intrasubunit S5-S6 pore domain site in Kv7.1, and a novel S6-S5'-E1 site at the intersubunit interface of Kv7.1/KCNE1, where the auxiliary KCNE1 subunit is critical. These findings highlight distinct binding modes compared to CBD's activating effects on neuronal Kv7 subtypes. This dual-site understanding provides a robust framework for rational drug design, aiming to develop Kv7 modulators that avoid cardiac off-target effects and enhance therapeutic precision.
0
Binding Site Resolution
0
AI Prediction Accuracy
0
Drug Selectivity Potential
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
2
Distinct Binding Sites Identified
Our research unequivocally identifies two separate binding sites for CBD in Kv7.1 and Kv7.1/KCNE1 channels, a key finding for targeted drug design and avoiding cardiac adverse effects.
| Feature | Kv7.1 Alone (S5-S6 Site) | Kv7.1/KCNE1 (S6-S5'-E1 Site) |
|---|---|---|
| Location | Intrasubunit pore domain (S5-S6 helices) | Intersubunit interface (between two Kv7.1 subunits and one KCNE1 subunit) |
| Key Interacting Residues | G272, F275, A336 (Kv7.1) | S338 (Kv7.1), F53, F57 (KCNE1) |
| KCNE1 Subunit Role | Not applicable | Creates and stabilizes novel binding pocket, influences S5-S6 site dynamics |
| CBD Efficacy | More potent inhibition (IC50 = 6 µM) | Less potent inhibition (IC50 = 14 µM) |
Integrated AI & Experimental Discovery Pipeline
AI-driven Binding Site Prediction (Chai-1)
→
Molecular Docking & MD Simulations
→
Site-Directed Mutagenesis
→
Electrophysiological Validation (Xenopus oocytes)
→
Elucidation of Biophysical Mechanisms
| Model | Prediction Capability | Validation Support | Impact on Discovery |
|---|---|---|---|
| Chai-1 AI Model | Generated initial CBD binding site predictions for Kv7.1 and Kv7.1/KCNE1 (ipTM scores 10-40) | Provided strong initial leads corroborated by mutagenesis and MD simulations | Enabled rapid identification of potential binding pockets, significantly reducing initial screening time. |
| Molecular Dynamics Simulations | Elucidated biophysical mechanisms, stability of binding poses, and pocket dynamics | Confirmed and refined AI-predicted binding modes, illustrating deeper interactions and KCNE1's modulatory role | Offered mechanistic understanding of CBD's inhibitory effects and guided experimental design for validation. |
Case Study: Rational Design for Cardiac-Safe Kv7 Modulators
Understanding the distinct CBD binding sites in cardiac Kv7.1 and Kv7.1/KCNE1 channels provides a crucial roadmap for precision drug development. This enables the rational design of new therapeutic compounds that can either selectively target specific Kv7 subtypes (e.g., neuronal Kv7s) while avoiding cardiac Kv7.1/KCNE1, or be designed to modulate these specific cardiac sites for treating arrhythmias. This approach significantly reduces the risk of proarrhythmic adverse effects, a common challenge with less selective ion channel drugs, thereby enhancing patient safety and accelerating the development of novel cardiac therapies.
$15M+
Potential Annual R&D Savings
By pinpointing binding mechanisms, AI accelerates lead identification and optimization, reducing preclinical failure rates and time-to-market for novel ion channel modulators.
Calculate Your AI-Driven R&D ROI
See how leveraging AI and mechanistic insights in drug discovery can significantly reduce costs and accelerate your therapeutic development pipeline.
Our AI Implementation Roadmap
A phased approach to integrate AI-driven insights into your drug discovery workflow for maximum impact.
Phase 1: AI Integration & Data Curation
Integrate AI models (e.g., Chai-1) with existing R&D pipelines. Curate and prepare proprietary structural and pharmacological datasets for model training and prediction, focusing on Kv7 channels.
Phase 2: Predictive Analysis & Lead Generation
Utilize AI to predict novel drug binding sites and generate potential lead compounds. Perform initial in silico docking and molecular dynamics simulations to prioritize candidates.
Phase 3: Experimental Validation & Optimization
Conduct site-directed mutagenesis and electrophysiological assays to validate AI predictions. Refine lead compounds based on experimental feedback, focusing on subtype selectivity and reduced off-target effects in cardiac Kv7.1/KCNE1.
Ready to Transform Your Drug Discovery with AI?
Schedule a personalized strategy session to explore how our AI-driven insights can accelerate your research and development, unlocking new therapeutic possibilities with enhanced precision and safety.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat